Literature DB >> 10091625

Effect of muscle activity immediately after botulinum toxin injection for writer's cramp.

R Chen1, B I Karp, S R Goldstein, W Bara-Jimenez, Z Yaseen, M Hallett.   

Abstract

Animal and human studies have shown that nerve stimulation enhances some effects of botulinum toxin (btx A) injection. Voluntary muscle activity might work similarly and would focus the effect of an injection into the active muscles. We studied the effects of exercise immediately after btx A injection in eight patients with writer's cramp with established response to btx A over two injection cycles with a single-blinded, randomized, crossover design. Immediately after the first study injection, they were randomly assigned to write continuously for 30 min or have their hand and forearm immobilized for 30 min. Following the second injection, they were assigned the alternate condition. Patients were assessed just before each injection, and at 2 weeks, 6 weeks, and 3 months post-injection. Assessment included objective strength testing, self-reported rating of benefit and weakness, and blinded evaluation of videotapes and writing samples of the patients writing a standard passage. Strength testing showed that the maximum weakness occurred at 2 weeks post-injection, but the benefit was maximum at 6 weeks post-injection. The "write" condition resulted in greater reduction in strength than the "rest" condition. Btx A treatment led to improvement in self-reported ratings, writer's cramp rating scale scores by blinded raters, and reduction in writing time, but the differences between the "write" and "rest" conditions were not significant. We conclude that voluntary muscle activity immediately after btx A injection leads to greater reduction in muscle strength. Our findings raise the possibility that voluntary muscle activation may allow reduction of btx A doses and favorably alter the balance of benefit and side effects of btx A injections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10091625     DOI: 10.1002/1531-8257(199903)14:2<307::aid-mds1016>3.0.co;2-3

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

1.  [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Authors:  J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

Review 2.  Evidence for the effectiveness of botulinum toxin for writer's cramp.

Authors:  K Dashtipour; R A Pender
Journal:  J Neural Transm (Vienna)       Date:  2008-03-06       Impact factor: 3.575

Review 3.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

Review 4.  Mechanism of action of botulinum neurotoxin: Unexpected consequences.

Authors:  Mark Hallett
Journal:  Toxicon       Date:  2017-08-11       Impact factor: 3.033

5.  Evidence for central antispastic effect of botulinum toxin type A.

Authors:  Ivica Matak
Journal:  Br J Pharmacol       Date:  2019-11-06       Impact factor: 8.739

6.  Vocal exercise versus voice rest following botulinum toxin injections: a randomized crossover trial.

Authors:  Randal C Paniello; Julia D Edgar; Joel S Perlmutter
Journal:  Ann Otol Rhinol Laryngol       Date:  2009-11       Impact factor: 1.547

7.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

Review 8.  Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.

Authors:  Wilhelm J Schulte-Mattler
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them.

Authors:  Mark Hallett
Journal:  Toxicon       Date:  2015-07-26       Impact factor: 3.033

Review 10.  Treatment of focal dystonias with botulinum neurotoxin.

Authors:  Mark Hallett; Reiner Benecke; Andrew Blitzer; Cynthia L Comella
Journal:  Toxicon       Date:  2008-12-13       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.